Outlook - Can open-source R&D reinvigorate drug research?

被引：71
作者：
Munos, Bernard [1 ]
机构：
[1] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA
来源：
NATURE REVIEWS DRUG DISCOVERY | 2006年 / 5卷 / 09期
基金：
美国国家卫生研究院; 英国惠康基金;
关键词：
OPEN-SOURCE SOFTWARE;
D O I：
10.1038/nrd2131
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
The low number of novel therapeutics approved by the US FDA in recent years continues to cause great concern about productivity and declining innovation. Can open-source drug research and development, using principles pioneered by the highly successful open-source software movement, help revive the industry?
引用
收藏
页码：723 / 729
页数：7
相关论文
共 19 条
[1]  
[Anonymous], THESIS AUSTR NATL U
[2]  
COLLINS FS, 2006, NIH ROADMAP NEW PATH
[3]  
Cukier KennethN., 2003, Acumen Journal of Life Sciences, V1, P54
[4]   NETWORKS OF INNOVATORS - A REVIEW AND INTRODUCTION TO THE ISSUE [J].
DEBRESSON, C ;
AMESSE, F .
RESEARCH POLICY, 1991, 20 (05) :363-379
[5]   The case for open-source software in drug discovery [J].
DeLano, WL .
DRUG DISCOVERY TODAY, 2005, 10 (03) :213-217
[6]  
DEMONACO HJ, 2005, 455205 MIT SLOAN
[7]   An enhanced version of SMMP-open-source software package for simulation of proteins [J].
Eisenmenger, F ;
Hansmann, UHE ;
Hayryan, S ;
Hu, CK .
COMPUTER PHYSICS COMMUNICATIONS, 2006, 174 (05) :422-429
[8]  
FELDMAN R, 2004, MINN J L SCI TECH, V6, P1
[9]   Technology licensing to non-traditional partners Non-profit health product development organizations for better global health [J].
Gardner, Charles ;
Garner, Cathy .
INDUSTRY AND HIGHER EDUCATION, 2005, 19 (03) :241-247
[10]   Optimizing the use of open-source software applications in drug discovery [J].
Geldenhuys, WJ ;
Gaasch, KE ;
Watson, M ;
Allen, DD ;
Van der Schyf, CJ .
DRUG DISCOVERY TODAY, 2006, 11 (3-4) :127-132
12